Spectranetics Cp T (SPNC) 24.86 $SPNC Spectranetics Has

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Spectranetics Cp T (SPNC) 24.86 $SPNC

Spectranetics Has Returned 25.8% Since SmarTrend Recommendation (SPNC)
Comtex SmarTrend(R) - Tue Aug 30, 1:41PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on July 7th, 2016 at $19.95. In approximately 2 months, Spectranetics has returned 25.82% as of today's recent price of $25.09.
SPNC: 24.86 (+0.17)

Spectranetics Shares Up 25.6% Since SmarTrend's Buy Recommendation (SPNC)
Comtex SmarTrend(R) - Tue Aug 23, 1:15AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on July 7th, 2016 at $19.95. In approximately 2 months, Spectranetics has returned 25.60% as of today's recent price of $25.05.
SPNC: 24.86 (+0.17)

Technical Roundup on Medical Appliances & Equipment Stocks -- Zimmer Biomet, Stryker, ABIOMED, and Spectranetics
PR Newswire - Thu Aug 18, 7:31AM CDT
Stock-Callers.com is currently focused on the Medical Appliances and Equipment segment, which includes companies that manufacture medical supplies such as surgical and medical instruments, dental equipment, and surgical appliances. According to IBISWorld, global revenue of this industry is about $350 billion. Let us take a look at today's lineup: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Stryker Corp. (NYSE: SYK), ABIOMED Inc. (NASDAQ: ABMD), and The Spectranetics Corp. (NASDAQ: SPNC). Sign up today and download for free the research reports for the stocks covered today at:
SPNC: 24.86 (+0.17), ABMD: 117.43 (-0.20), ZBH: 129.40 (+1.05), SYK: 115.60 (+0.37)

First Randomized Trial of the Stellarex(TM) Drug-coated Balloon Presented at the Amputation Prevention Symposium
GlobeNewswire - Wed Aug 10, 4:58PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Marianne Brodmann of Medical University Graz, Austria, presented the final 12-month results of the Stellarex Drug-coated Balloon ILLUMENATE European Randomized Clinical Trial (EU RCT) at the Amputation Prevention Symposium (AMP) in Chicago, Illinois. The EU RCT Trial enrolled 328 patients, 295 of whom were randomized to treatment with the Stellarex drug-coated balloon (DCB) or a percutaneous transluminal angioplasty (PTA). The key results at day 365 include:
SPNC: 24.86 (+0.17)

Spectranetics Receives CE Mark for AngioSculptX(TM)
GlobeNewswire - Wed Aug 10, 8:00AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of CE marking for the AngioSculptX Drug-coated PTCA Scoring Balloon Catheter. AngioSculptX is a first-of-its-kind device, combining the proven AngioSculpt PTCA scoring balloon catheter with a drug coating. It is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis.
SPNC: 24.86 (+0.17)

Downgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Wed Aug 10, 3:27AM CDT
Spectranetics (NASDAQ:SPNC) was downgraded from Strong Buy to Buy at Needham today. The stock closed yesterday at $24.03 on volume of 445,000 shares, below average daily volume of 703,000. The Spectranetics Corporation develops, manufactures, markets, and distributes its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is used in applications such as coronary angioplasty and the removal of pacemaker leads. Spectranetics is also developing other applica- tions in restenosis stents and peripheral vascular applications.
SPNC: 24.86 (+0.17)

Upgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Thu Aug 04, 3:16AM CDT
Spectranetics (NASDAQ:SPNC) was upgraded from Sell to Buy at UBS today. The stock closed yesterday at $23.67 on volume of 1.1 million shares, above average daily volume of 703,000. The Spectranetics Corporation develops, manufactures, markets, and distributes its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is used in applications such as coronary angioplasty and the removal of pacemaker leads. Spectranetics is also developing other applica- tions in restenosis stents and peripheral vascular applications.
SPNC: 24.86 (+0.17)

Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million
GlobeNewswire - Thu Jul 28, 3:01PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended June 30, 2016. Highlights of the quarter, all compared with the three months ended June 30, 2015, include:
SPNC: 24.86 (+0.17)

Uptrend Call Working As Spectranetics Stock Rises 28.4% (SPNC)
Comtex SmarTrend(R) - Fri Jun 10, 1:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 28.41% as of today's recent price of $19.82.
SPNC: 24.86 (+0.17)

How are These Healthcare Stocks Faring? - Zimmer Biomet, Wright Medical, Spectranetics and Prestige Brands
PR Newswire - Fri Jun 03, 7:00AM CDT
In today's pre-market coverage, ActiveWallSt.com has these four Medical Appliances and Equipment stocks lined up for investors to review: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Wright Medical Group N.V. (NASDAQ: WMGI), The Spectranetics Corp. (NASDAQ: SPNC), and Prestige Brands Holdings Inc. (NYSE: PBH). Register now to access these stocks' trade alerts by clicking on the following link:
SPNC: 24.86 (+0.17), ZBH: 129.40 (+1.05), WMGI: 24.71 (+0.10), PBH: 47.99 (+0.29), WMGIZ: 1.35 (unch)

Shares of SPNC Up 26.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:55PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 26.27% as of today's recent price of $19.49.
SPNC: 24.86 (+0.17)

Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics' Stellarex drug-coated balloon at NCVH
GlobeNewswire - Wed Jun 01, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Dr. Prakash Krishnan of Mount Sinai Medical Center, New York, NY presented the second interim analysis of 12-month data from the ILLUMENATE Global Study at the New Cardiovascular Horizons annual conference in New Orleans, Louisiana. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 24.86 (+0.17)

SmarTrend Watching for Potential Pullback in Shares of Spectranetics After 5.77% Gain
Comtex SmarTrend(R) - Mon May 23, 4:32PM CDT
Spectranetics (NASDAQ:SPNC) traded in a range yesterday that spanned from a low of $16.56 to a high of $17.72. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $17.39 on volume of 534,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SPNC: 24.86 (+0.17)

Spectranetics to Present at the UBS Global Healthcare Conference
GlobeNewswire - Wed May 11, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Chief Financial Officer Stacy McMahan will be presenting at the UBS Global Healthcare Conference on May 25, 2016, at the Grand Hyatt in New York City.
SPNC: 24.86 (+0.17)

Spectranetics reports 1Q loss
Automated Insights - Thu Apr 28, 6:28PM CDT
COLORADO SPRINGS, Colo. (AP) _ The Spectranetics Corp. (SPNC) on Thursday reported a loss of $17.3 million in its first quarter.
SPNC: 24.86 (+0.17)

Spectranetics Achieves First Quarter 2016 Revenue of $62.9 million
GlobeNewswire - Thu Apr 28, 3:01PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended March 31, 2016. Highlights of the quarter, all compared with the three months ended March 31, 2015, include:
SPNC: 24.86 (+0.17)

12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics' Stellarex drug-coated balloon at Charing Cross
GlobeNewswire - Tue Apr 26, 5:30AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Thomas Zeller presented 12-month interim data from the ILLUMENATE Global Study at the Charing Cross Symposium in London, England. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 24.86 (+0.17)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 0

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 0

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed Alleging Eye Injury from Ozempic Use

Updated Category News Views 165

Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....

Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call

Updated Category News Views 151

C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...

Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI

Updated Category News Views 173

PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...

Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer

Updated Category News Views 199

Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...

Continue Reading
Exploring the Future of Organic Infant Formula Market Growth

Updated Category News Views 275

Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...

Continue Reading